The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection

ConclusionOur observations indicate that serum TRAcP5b, measured at 6  months after a Dmab injection, is not a useful early marker for time-dependent increased accumulation of osteoclasts in humans and for identification of patients at risk for a higher rebound increase in bone resorption.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research